AXAxsome Therapeutics AXSM · NASDAQ
$161.79 -0.27% (-$0.43)
- Market cap
- $8.33B
- Enterprise value
- $8.23B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 10.7x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -50.9%
- Gross margin
- 93.2%
- Net margin
- -24.7%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.60
- Free float
- 84.3%
About the company
Axsome Therapeutics, Inc. (AXSM) is a biotechnology company focused on the development and commercialization of innovative drugs for the treatment of various neurologic and psychiatric disorders. The company targets therapeutic areas such as depression, migraines, Alzheimer's disease, and other neurological conditions that have a significant impact on human health. Axsome Therapeutics aims to improve the quality of life for patients by offering novel and effective treatment options. With active research and clinical trials, the company has a promising pipeline of drugs that can have a positive impact on healthcare and the medical industry. Investing in Axsome Therapeutics, Inc. (AXSM) shares can be an attractive choice for investors who follow the biotechnology and pharmaceutical sectors and seek a company with the potential for significant growth and innovative treatment approaches.
Sector
Healthcare
Industry
Biotechnology
CEO
Herriot Tabuteau
Employees
1,346
Headquarters
New York City
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number